Mylan surges, Teva slumps after FDA okays Copaxone copy

(Reuters) - Shares in Mylan jumped 16 percent in premarket trading on Wednesday after the U.S. Food and Drug Administration approved the drugmaker's generic version of Teva blockbuster multiple sclerosis drug Copaxone.